Balyasny Asset Management LLC raised its holdings in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) by 13.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 246,300 shares of the biopharmaceutical company’s stock after buying an additional 28,800 shares during the quarter. Balyasny Asset Management LLC owned about 0.48% of Tetraphase Pharmaceuticals worth $1,756,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. UBS Group AG grew its position in shares of Tetraphase Pharmaceuticals by 2.3% in the 1st quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 387 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in shares of Tetraphase Pharmaceuticals by 0.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 129,681 shares of the biopharmaceutical company’s stock worth $925,000 after buying an additional 874 shares during the last quarter. American International Group Inc. grew its position in shares of Tetraphase Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 22,390 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 1,486 shares during the last quarter. Citadel Advisors LLC grew its position in shares of Tetraphase Pharmaceuticals by 18.6% in the 1st quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 2,496 shares during the last quarter. Finally, Rhumbline Advisers grew its position in shares of Tetraphase Pharmaceuticals by 5.7% in the 2nd quarter. Rhumbline Advisers now owns 51,633 shares of the biopharmaceutical company’s stock worth $368,000 after buying an additional 2,780 shares during the last quarter. Hedge funds and other institutional investors own 41.73% of the company’s stock.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.07). Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The business had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $1.54 million. During the same quarter in the previous year, the company posted ($0.47) earnings per share. The company’s quarterly revenue was up 28.2% compared to the same quarter last year.

WARNING: This story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/10/13/tetraphase-pharmaceuticals-inc-ttph-stake-raised-by-balyasny-asset-management-llc.html.

TTPH has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 6th. HC Wainwright initiated coverage on Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They issued a “buy” rating and a $15.00 price objective on the stock. Stifel Nicolaus upgraded Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $8.00 to $15.00 in a research report on Wednesday, July 26th. BMO Capital Markets reiterated an “outperform” rating and issued a $13.00 price objective (up from $12.00) on shares of Tetraphase Pharmaceuticals in a research report on Wednesday, July 26th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. Tetraphase Pharmaceuticals has an average rating of “Hold” and an average target price of $12.96.

In other news, insider Jacques Dumas sold 17,500 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $6.00, for a total value of $105,000.00. Following the sale, the insider now directly owns 17,500 shares in the company, valued at $105,000. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 5.50% of the company’s stock.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.